SALT LAKE CITY, UT / ACCESSWIRE / August 26, 2024 / KindlyMD, Inc. ("KindlyMD" or the "Company") (NASDAQ:KDLY), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, is pleased to announce that KindlyMD CEO, Tim Pickett, will participate in H.C. Wainwright's 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 9-11, 2024.
Mr. Pickett will present virtually, as well as take part in one-on-one investor meetings during the conference.
H.C. Wainwright 26th Annual Global Investment Conference
Date: September 9-11, 2024
Time: Presentation available on demand from 7:00 a.m. ET
Location: Lotte New York Palace Hotel, New York
Speaker: Tim Pickett, CEO
Webcast: https://journey.ct.events/view/c4d3d1ce-2ac4-43a6-ac75-8ff358a8f3d9
To schedule a one-on-one investor meeting with Mr. Pickett, please contact your H.C. Wainwright representative or KCSA Strategic Communications at This email address is being protected from spambots. You need JavaScript enabled to view it..
A replay of this presentation will be available for at least 90 days following the date of the presentation on the Company's website at https://investors.kindlymd.com/events-presentations.
About KindlyMD
KindlyMD™️ is a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies to offer patients comprehensive care and reduce the addiction and dependency of opioid use in the U.S. KindlyMD currently operates four centers including the largest alternative pain treatment center in Utah. With a focus on holistic pain management through its specialty outpatient clinical services, including, where appropriate, the recommendation of medical cannabis by KindlyMD healthcare providers, KindlyMD is providing better patient health outcomes.
For more information, please visit www.kindlymd.com.
Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
(212) 896-1254
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$24.94 |
Daily Volume: | 0 |
Market Cap: | US$149.140M |
January 22, 2025 November 13, 2024 October 29, 2024 October 08, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load